Brief: Aquestive Therapeutics Receives Positive FDA Written Response For Aqst-109 Epinephrine Sublingual Film
11/10/2022 13:03
Oct 11 (Reuters) - Aquestive Therapeutics Inc AQST.O :
* AQUESTIVE THERAPEUTICS RECEIVES POSITIVE FDA WRITTEN
RESPONSE
FOR AQST-109 EPINEPHRINE SUBLINGUAL FILM
* AQUESTIVE THERAPEUTICS INC - FDA END-OF-PHASE 2 MEETING
FOR
CLINICAL FEEDBACK SCHEDULED FOR LATER THIS QUARTER
* AQUESTIVE THERAPEUTICS INC - CONFIRMS AGENCY ALIGNMENT ON
PLANNED STABILITY PACKAGES FOR BOTH API AND DRUG PRODUCT
* AQUESTIVE THERAPEUTICS RECEIVES POSITIVE FDA WRITTEN
RESPONSE
FOR AQST-109 EPINEPHRINE SUBLINGUAL FILM
Source text for Eikon: ID:nGNX97sgZM
Further company coverage: AQST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million